Sidi Chen

Sidi Chen

Auto-generated profile, based on publicly available information

Sidi Chen

Department of Genetics, Yale University School of Medicine, New haven, CT, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in Nature Reviews Methods Primers
Verified
Journal Article
Closed access
PDF file
CBChristoph Bock
Christoph Bock
PDPaul Datlinger
Paul Datlinger
FCFlorence Chardon
Florence Chardon
MCMatthew A. Coelho
Matthew A. Coelho
MDMatthew B. Dong
Matthew B. Dong
XZXiaowei Zhuang
Xiaowei Zhuang

12 August 2024 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
LPLei Peng
Lei Peng
GSGiacomo Sferruzza
Giacomo Sferruzza
LYLuojia Yang
Luojia Yang
LZLiqun Zhou
Liqun Zhou
SCSidi Chen
Sidi Chen
In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach for combating cancers, demonstrating remarkable efficacy in relapsed/refractory hematological malignancies in both pediatric and adult patients. CAR-natural killer (CAR-NK) cell complements CAR-T cell therapy by offering several distinct advantages. CAR-NK cells do not require HLA compatibility and exhibit low safety concerns. Moreover, CAR-NK cells are conducive to “off-the-shelf” therapeutics, providing significant logistic advantages over CAR-T cells. Both CAR-T and CAR-NK cells have shown consistent and promising results in hematological malignancies. However, their efficacy against solid tumors remains limited due to various obstacles including limited tumor trafficking and infiltration, as well as an immuno-suppressive tumor microenvironment. In this review, we discuss the recent advances and current challenges of CAR-T and CAR-NK cell immunotherapies, with a specific focus on the obstacles to their application in solid tumors. We also analyze in depth the advantages and drawbacks of CAR-NK cells compared to CAR-T cells and highlight CAR-NK CAR optimization. Finally, we explore future perspectives of these adoptive immunotherapies, highlighting the increasing contribution of cutting-edge biotechnological tools in shaping the next generation of cellular immunotherapy.

1 August 2019 in Cell
Verified
Journal Article
Closed access
MDMatthew B. Dong
Matthew B. Dong
GWGuangchuan Wang
Guangchuan Wang
RCRyan D. Chow
Ryan D. Chow
LYLupeng Ye
Lupeng Ye
LZLvyun Zhu
Lvyun Zhu
SCSidi Chen
Sidi Chen

10 February 2022 in Nature Reviews Methods Primers
Verified
Journal Article
Closed access
PDF file
CBChristoph Bock
Christoph Bock
PDPaul Datlinger
Paul Datlinger
FCFlorence Chardon
Florence Chardon
MCMatthew A. Coelho
Matthew A. Coelho
MDMatthew B. Dong
Matthew B. Dong
XZXiaowei Zhuang
Xiaowei Zhuang

14 August 2017 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
RCRyan D Chow
Ryan D Chow
CGChristopher D Guzman
Christopher D Guzman
GWGuangchuan Wang
Guangchuan Wang
FSFlorian Schmidt
Florian Schmidt
MYMark W Youngblood
Mark W Youngblood
SCSidi Chen
Sidi Chen
Using an adeno-associated virus–mediated, direct in vivo CRISPR screen, the authors mapped a quantitative landscape of glioblastoma suppressors. Their study revealed gene combinations that functionally drive gliomagenesis from normal glia in native mouse brains. The authors further demonstrate that mutational background can differentially influence gene expression and chemotherapeutic resistance. A causative understanding of genetic factors that regulate glioblastoma pathogenesis is of central importance. Here we developed an adeno-associated virus–mediated, autochthonous genetic CRISPR screen in glioblastoma. Stereotaxic delivery of a virus library targeting genes commonly mutated in human cancers into the brains of conditional-Cas9 mice resulted in tumors that recapitulate human glioblastoma. Capture sequencing revealed diverse mutational profiles across tumors. The mutation frequencies in mice correlated with those in two independent patient cohorts. Co-mutation analysis identified co-occurring driver combinations such as B2m–Nf1, Mll3–Nf1 and Zc3h13–Rb1, which were subsequently validated using AAV minipools. Distinct from Nf1-mutant tumors, Rb1-mutant tumors are undifferentiated and aberrantly express homeobox gene clusters. The addition of Zc3h13 or Pten mutations altered the gene expression profiles of Rb1 mutants, rendering them more resistant to temozolomide. Our study provides a functional landscape of gliomagenesis suppressors in vivo.

10 March 2022 in Cell Metabolism
Verified
Journal Article
Closed access
LYLupeng Ye
Lupeng Ye
JPJonathan J. Park
Jonathan J. Park
LPLei Peng
Lei Peng
QYQuanjun Yang
Quanjun Yang
RCRyan D. Chow
Ryan D. Chow
SCSidi Chen
Sidi Chen